ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]